Hologic Inc announced it received U.S. Food and Drug Administration (FDA) clearance for its Single Energy (SE) Femur Exam on a dual energy x-ray absorptiometry (DXA) platform for the assessment offeatures associated with atypical femur fractures (AFF).
The new assessment option will be offered exclusively on Hologic’s Horizon DXA platform, a soon to be commercialized product line of bone densitometers. This quick 15-second SE Femur Exam is designed to produce a high resolution image of the entire femur with a very low effective radiation dose.
An AFF assessment can be conveniently performed at the time of a hip bone density scan with little or no patient repositioning and a minimal increase in exam time.
This first-of-its-kind capability assists clinicians in their assessment of potential AFF in patients who have been on anti-resorptive treatments such as bisphosphonates.
[source: Hologic]
